INSULIN SENSITIVITY OF OBESE HYPERTENSIVE SUBJECTS

溴隐亭，一种具有5-羟色胺拮抗剂的交感多巴胺D2激动剂 活动，已被证明可以抑制季节性发展， 肥胖相关的葡萄糖耐受不良的仓鼠;部分通过重置 昼夜节律的下丘脑神经活动已知调节这一年度 周期 自从Ergoset（ERG），一种新的快速释放配方， 溴隐亭，已被证明可以改善血糖控制， 2型糖尿病患者，本研究开始于 患者评价ERG对空腹和餐后水平的影响 各种激素，以及12名肥胖者的葡萄糖和脂质水平， 高胰岛素血症非糖尿病女性。

Bromocriptine, a sympathic dopamine D2 agonist with serotonin antagonist activities, has been demonstrated to inhibit the seasonal development of obesity-related glucose intolerance in hamsters; in part by resetting circadian hypothalamic neural activities known to regulate this annual cycle. Since Ergoset (ERG), a new quick release formulation of bromocriptine, has been demonstrated to improve glycemic control in patients with Type 2 diabetes, the present study was initiated in patients to evaluate the effect of ERG on fasting and postprandial levels of various hormones, as well as glucose and lipid levels in 12 obese, hyperinsulinemic, non-diabetic women.